arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

RELMADA THERAPEUTICS, INC.

RLMD
$3.77 ▼ -0.48 (-11.29%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
59 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

RELMADA THERAPEUTICS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $423.7M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -5.7%
FCF / Share $-0.09
Trailing P/E
Price / Book 2.0x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

59-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$634.00
↑ +58.5%
Net Income Profit after all expenses
$-19.05M
↓ -8.5%
Operating Margin Operating profit as % of sales
-479.4%
↓ -5643.6%
FCF / Share Free cash flow per share
$-0.09
↑ +50.9%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
13
Cash Quality
54

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 15 years · 59 quarters